The Decision

In some instances, such as when someone has an unknown genetic disease, sequencing the genome makes sense to get to the cause of the disease, the Wall Street Journal says, but it adds: What about when people are healthy? Stanford University's Atul Butte and Robert Green from Brigham and Women's Hospital and Harvard Medical School take up the debate.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

To Tell?

The Coming Changes

Off and Running

Source of the Fever

This Week in Nucleic Acids Research: Researchers describe a new method to find large-scale structural variants in cancer genomes, a glimpse at an approach for profiling miRNAs in tumor samples from TCGA, and more.

Intellia Therapeutics has raised $70 million, becoming the latest firm leveraging the gene editing technology to haul in a gob of cash.

Now going beyond reporting fetal aneuploidies, NIPTs may be providing too much information that may be useless, some doctors and genetic counselor say.

A group of organizations in the UK say that there needs to be discussions about the use of technologies such as CRISPR/Cas-9 for human germline editing.